he latest report on clinical trials in the Alzheimer’s drug development pipeline points to the growing potential of anti-amyloid monoclonal antibodies for treating the brain-robbing condition. Anti-inflammatory agents comprise the single largest therapeutic category with 25 drugs, but astoundingly no two are aimed at the same target, according to lead author Jeffrey Cummings, M.D., research professor in the school of integrated health sciences at the University of Nevada, Las Vegas, and director of its Chambers-Grundy Center for Transformative Neuroscience.

Newly approved anti-amyloid therapies have spurred hope for patients and caregivers affected by Alzheimer's disease, but access to these drugs could be stymied by a lack of convenient and available beta-amyloid testing options.

Up to 50 percent of people in the U.S. with Alzheimer’s receive an imprecise or inaccurate diagnosis of their cognitive condition. The tools typically used to detect the disease, like a PET scan, can cost thousands of dollars and are generally only available in places with large medical institutions. And African Americans are 35 percent less likely to be diagnosed than their White counterparts.

More than 6.7 million individuals in the U.S. have Alzheimer’s disease, and that number is growing rapidly. Each day that passes without effective treatments brings tragic consequences for patients and their loved ones. As the debate over coverage for new Alzheimer’s drugs continues,  Dr. Jeffrey Cummings of the University of Nevada, Las Vegas, joined us to discuss the challenging path that led to these medicines, the state of the science now, and hope for the future.

KNX In Depth's Charles Feldman and Rob Archer discuss a new study that looks into Alzheimer's research and drugs. It sounds optimistic when it comes to the future of treating the disease.

Several studies say simple lifestyle choices help preserve thinking and memory.

There are, at this moment, 187 clinical trials for the neurodegenerative disease underway, the highest ever on record, according to a new report from the Alzheimer’s Association (AA). The research was published in the association’s journal, Alzheimer’s & Dementia: Translational Research and Clinical Interventions, last week, featuring data scraped from the ClinicalTrials.gov database.

The health of your microbiome (gut bacterial flora) can affect your overall health. Past research has shown the correlation between microbiomes and diseases like Alzheimer’s and other form of dementia. Recently, clinical investigators from the University of Nevada, Las Vegas identified 10 specific types of bacteria in the gut of individuals linked with the likelihood of developing Alzheimer’s disease.

According to the World Health Organization, Alzheimer's is one of our most debilitating diseases. It effectively erases who you are, insinuating itself at first with annoyance, then anger, then fright, and finally silence. It can take 20 years to play out, exhausting caregivers, family, and friends.

More than 6 million Americans are living with Alzheimer's disease, a staggering number that's expected to double within the next 30 years.

New research is showing that an abundance of certain specific types of gut bacteria could be associated with the likelihood of developing Alzheimer's disease.

A growing body of evidence suggests that an imbalance of the human gut microbiome is associated with the development of neurodegenerative diseases like Alzheimer’s disease (AD) via neuroinflammatory processes across the gut-brain axis. Now, researchers at the University of Las Vegas have identified 10 bacterial groups associated with Alzheimer’s disease, providing new insights into the relationship between the gut and dementia.